Novo Nordisk Plans to Make Insulin More Affordable With New Program, Authorized Generics

Beginning January 2, 2020, Novo Nordisk will be providing new pricing options for their insulin products in the US to support patients without insurance.

The new offerings include:

• $99.00 Cash Card Program for Analog Insulins: Patients will be allowed to purchase up to 3 vials or 2 packs of FlexPen/FlexTouch pens of any combination of Novo Nordisk analog insulins (3000-3600 Units total depending on brands) for $99.00.
• Authorized Generics of Novolog and Novolog Mix: Insulin Aspart and Insulin Aspart Protamine/Insulin Aspart (Insulin Aspart Mix) will be made available in vials and pens at a 50% reduced price compared to the current listed price of the branded versions:
  • Insulin Aspart 10mL vial/1000 Units: $144.68
  • Insulin Aspart 5x3mL Penfill/1500 Units: $268.73
  • Insulin Aspart 5x3mL FlexPen/1500 Units: $279.41
  • Insulin Aspart Mix 70/30 10mL vial/1000 Units: $150.06
  • Insulin Aspart Mix 70/30 5x3mL FlexPen/1500 Units: $279.41

Novo Nordisk will continue to supply the branded versions for patients who wish to continue taking Novolog and Novolog Mix.

Additionally, the Company has affordability options already in place, including a patient assistance program and co-pay savings cards.

“People with diabetes need more affordable options and we are going to continue doing what we can now while also working with other healthcare stakeholders on longer-term system reform. For instance, we support the recent IRS ruling that classifies diabetes medications as preventive care. We believe this has the potential to help a significant number of people with diabetes from an affordability perspective,” said Doug Langa, executive vice president, North America Operations and president of Novo Nordisk Inc. 

For more information visit novonordisk-us.com.